PureTech Health plc (NASDAQ:PRTC – Get Rating) was the target of a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 600 shares, a growth of 100.0% from the October 15th total of 300 shares. Based on an average daily trading volume, of 3,100 shares, the short-interest ratio is presently 0.2 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in PureTech Health stock. AWM Investment Company Inc. increased its position in shares of PureTech Health plc (NASDAQ:PRTC – Get Rating) by 2,100.0% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 660,000 shares of the company's stock after purchasing an additional 630,000 shares during the period. AWM Investment Company Inc. owned approximately 2.32% of PureTech Health worth $2,513,000 as of its most recent SEC filing. Institutional investors and hedge funds own 2.32% of the company's stock.

Analysts Set New Price Targets

Separately, Piper Sandler upped their target price on shares of PureTech Health from $37.00 to $44.00 and gave the company an "overweight" rating in a report on Thursday, August 25th.

PureTech Health Stock Up 0.2 %

PureTech Health Company Profile

(Get Rating)

PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions.

Featured Articles

• Get a free copy of the StockNews.com research report on PureTech Health (PRTC)
• Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
• Six Flags is a Ride You Don't Want to Get Stuck On
• Vision Hydrogen, Now Vision Energy, Puts Hopes In Stock Split
• Hanesbrands May be Signaling a Bad Week for Retail Stocks
• Coupang Stock And Why You Should Care

Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.